Evaluation of serum levels of HER2, MMP-9, nitric oxide, and total antioxidant capacity in Egyptian breast cancer patients: Correlation with clinico-pathological parameters

Scientia Pharmaceutica

Volumn 82, Issue 1, 2014, Pages 129-145

  Rashad, Yara A ^a   Elkhodary, Tawfik R ^a   El Gayar, Amal M ^a   Eissa, Laila A ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Breast cancer; Carcinoma antigen 15 3 (CA15 3); Human epidermal growth factor receptor 2 (HER2); Matrix metalloproteinase 9 (MMP 9); Nitric oxide (NO); Total antioxidant capacity (TAC)

Indexed keywords

CA 15-3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GELATINASE B; NITRIC OXIDE; PROGESTERONE RECEPTOR;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER STAGING; COLORIMETRY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; TUMOR VOLUME;

EID: 84896858448     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1306-18     Document Type: Article

References (35)

1. Hortobagyi GN, de la Garza, Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O'Shaughnessy JA, Shen ZZ, Albain KS. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005; 6: 391-401. http://dx.doi.org/10.3816/CBC.2005.n.043
2. Denewer A, Farouk O, Mostafa W, Elshamy K. Social support and hope among egyptian women with breast cancer after mastectomy. Breast Cancer (Auckl). 2011; 5: 93-103. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117623/
3. Roy V, Perez EA.Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist. 2009; 14: 1061-1069. http://dx.doi.org/10.1634/theoncologist.2009-0142
4. Tsé C, Gauchez AS, Jacot W, Lamy PJ. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev. 2012; 38:133-142. http://dx.doi.org/10.1016/j.ctrv.2011.03.008
5. Allison M.The HER2 testing conundrum. Nat Biotechnol. 2010; 28: 117-119. http://dx.doi.org/10.1038/nbt0210-117
6. Lam L, McAndrew N, Yee M, Fu T, Tchou JC, Zhang H. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta. 2012; 1826: 199-208. http://www.ncbi.nlm.nih.gov/pubmed/22521738
7. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci. 2006; 11: 479-491. http://dx.doi.org/10.2741/1811
8. Sanderson MP, Dempsey PJ, Dunbar AJ. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors. 2006; 24: 121-136. http://dx.doi.org/10.1080/08977190600634373
9. Stankovic S, Konjevic G, Gopcevic K, Jovic V, Inic M, Jurisic V. Activity of MMP-2 and MMP-9 in sera of breast cancer patients. Pathol Res Pract. 2010; 206: 241-247. http://dx.doi.org/10.1016/j.prp.2009.12.003
10. Choudhari SK, Chaudhary M, Bagde S, Gadbail AR, Joshi V. Nitric oxide and cancer: a review. World J Surg Oncol. 2013; 11: 118. http://dx.doi.org/10.1186/1477-7819-11-118
11. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer. 2006; 6: 521-534. http://dx.doi.org/10.1038/nrc1910
12. Sener DE, Gönenç A, Akinci M, Torun M. Lipid peroxidation and total antioxidant status in patients with breast cancer. Cell Biochem Funct. 2007; 25: 377-382. http://dx.doi.org/10.1002/cbf.1308
13. Park NK, Woo HD, Sohn DM, Kim SY, Lim CW, Choi TY, Kim JJ, Lee MH. The correlation of serum HER-2/neu and CA15-3 in patients with metastatic breast cancer. J Breast Cancer. 2008; 11: 18-24. http://dx.doi.org/10.4048/jbc.2008.11.1.18
14. Müller V, Witzel I, Pantel K, Krenkel S, Lück HJ, Neumann R, Keller T, Dittmer J, Jänicke F,Thomssen C.Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res. 2006; 26: 1479-1487. http://www.ncbi.nlm.nih.gov/pubmed/16619561
15. Leary AF, Hanna WM, van de Vijver MJ, Penault-Llorca F, Rüschoff J, Osamura RY, Bilous M, Dowsett M. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol. 2009; 27: 1694-1705. http://dx.doi.org/10.1200/JCO.2008.17.3989
16. Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C, Rulli A, Crinò L. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol. 2008; 19: 883-890. http://dx.doi.org/10.1093/annonc/mdm585
17. Tsai HP, Chen SC, Chien HT, Jan YY, Chao TC, Chen MF, Hsieh LL. Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer. World J Surg Oncol. 2012; 10:42. http://dx.doi.org/10.1186/1477-7819-10-42
18. Ratnatunga N, Liyanapathirana LV. Hormone receptor expression and Her/2neu amplification in breast carcinoma in a cohort of Sri Lankans. Ceylon Med J. 2007; 52: 133-136. http://www.ncbi.nlm.nih.gov/pubmed/18286776
19. Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M, Boudawara T. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breastcarcinoma. World J Surg Oncol. 2008; 6: 112. http://dx.doi.org/10.1186/1477-7819-6-112
20. Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, Koga T, Morita M, Kakeji Y, Maehara Y. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat. 2007; 101: 249-257. http://dx.doi.org/10.1007/s10549-006-9295-8
21. Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Munoz M, Farrus B, Ballesta AM. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. Anticancer Res. 2003; 23: 1043-1050. http://www.ncbi.nlm.nih.gov/pubmed/12820345
22. Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, Carney W, Allard JW, Lipton A. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem. 2002; 48: 1314-1320. http://www.ncbi.nlm.nih.gov/pubmed/12142389
23. Atoum M, Nimer N, Abdeldayem S, Nasr H. Relationships among serum CA15-3 tumor marker, TNM staging, and estrogen and progesterone receptor expression in benign and malignant breast lesions. Asian Pac J Cancer Prev. 2012; 13: 857-860. http://dx.doi.org/10.7314/APJCP.2012.13.3.857
24. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des. 2007; 13: 333-346. http://dx.doi.org/10.2174/138161207779313551
25. La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer. 2004; 90: 1414-1421. http://dx.doi.org/10.1038/sj.bjc.6601725
26. Patel S, Sumitra G, Koner BC, Saxena A. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clin Biochem. 2011; 44: 869-872. http://dx.doi.org/10.1016/j.clinbiochem.2011.04.019
27. Köhrmann A, Kammerer U, Kapp M, Dietl J, Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer. 2009; 9: 188. http://dx.doi.org/10.1186/1471-2407-9-188
28. Daniele A, Zito AF, Giannelli G, Divella R, Asselti M, Mazzocca A, Paradiso A, Quaranta M. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res. 2010; 30: 3521-3527. http://www.ncbi.nlm.nih.gov/pubmed/20944132
29. Günel N, Coşkun U, Sancak B, Günel U, Hasdemir O, Bozkurt S. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer. 2002; 95: 663-667. http://dx.doi.org/10.1002/cncr.10705
30. Konukoglu D, Turhan MS, Celik V, Turna H. Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients. Indian J Med Res. 2007; 125: 747-751. http://www.ncbi.nlm.nih.gov/pubmed/17704550
31. Muntané J, la Mata MD. Nitric oxide and cancer. World J Hepatol. 2010; 2: 337-344. http://dx.doi.org/10.4254/wjh.v2.i9.337
32. Vieira FG, Di Pietro PF, Boaventura BC, Ambrosi C, Rockenbach G, Fausto MA, Crippa CG, DaSilva EL.Factors associated with oxidative stress in women with breast cancer. Nutr Hosp. 2011; 26: 528-536. http://www.ncbi.nlm.nih.gov/pubmed/21892571
33. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002; 20: 3628-3636. http://dx.doi.org/10.1200/JCO.2002.02.026
34. Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L, Hudis C. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol. 2005; 16: 234-239. http://dx.doi.org/10.1093/annonc/mdi059
35. Koracevic D, Koracevic G, Djordjevic V, Andrejevic S, Cosic V. Method for the measurement of antioxidant activity in human fluids. J Clin Pathol. 2001; 54: 356-361. http://dx.doi.org/10.1136/jcp.54.5.356